Clinical Trials Browser

Recruiting × OTHER × Hemostatic Disorders × Clear all

Anemia, Aplastic, Anemia, Hemolytic, Autoimmune, Hemophilia B, Hemoglobinuria, Paroxysmal, Hemophilia A, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Hemostatic Disorders, Leukemia, Large Granular Lymphocytic

NCT07384013 2026-02-03

Study Protocol: Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs

Phase NA Recruiting

30 enrolled

Agnosia, Hemostatic Disorders

NCT07205523 2025-10-03

HALO-SCT

Recruiting

1,000 enrolled

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Aplastic, Hemophilia A, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hemostatic Disorders

NCT06644443 2024-10-16

BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma

Phase 1/2 Recruiting

10 enrolled

LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT06250595 2024-02-09

ENROL

Recruiting

37,090 enrolled

Classical hematologyOther hematologic neoplasmPlasma cell

Bone Marrow Failure Disorders, Anemia, Anemia, Sickle Cell, Leukemia, Thalassemia, Iron Metabolism Disorders, Hematologic Neoplasms, Hemostatic Disorders, Neoplasms, Plasma Cell

Clinical Trials

NICHE

Study Protocol: Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs

HALO-SCT

BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma

ENROL